A spreading virus, an adapting response
In the Democratic Republic of the Congo, the Ebola virus disease outbreak remains a race against time. In Bunia, the capital of Ituri, health teams have chosen to move forward with a clinical trial rather than rely solely on emergency measures. The message is clear: when transmission becomes prolonged, care, surveillance and science must be combined.
This decision comes in a country where the epidemic has passed a grim threshold. As of 19 September 2026, the DRC had recorded 7,672 confirmed cases and 3,699 deaths, according to the latest report from the National Institute of Public Health, cited by several media outlets and echoed by the response coordination team. The case fatality rate stood at 48.2%, with 1,879 people recovered and 886 patients hospitalised or in isolation.
Ituri, North Kivu and a nationwide epidemic
The epicentre remains Ituri, in the north-east of the country. But the disease is no longer confined to a single province. Response bulletins show it spreading across several health zones and, more broadly, into seven provinces. This expansion changes the nature of the response: it is no longer just a local outbreak, but a public health challenge on a national scale.
The DRC is no stranger to the fight against Ebola. The World Health Organization says this is the 17th outbreak recorded in the country since the virus was identified in 1976. This long experience explains the speed of some institutional responses, but it does not erase the challenges on the ground: population movements, unequal access to healthcare, contact tracing and sometimes fragile trust between communities and medical teams.
Ervebo vaccine tested against the Bundibugyo strain
In Bunia, the clinical trial launched by the Congolese authorities is testing the Ervebo vaccine. About 20,000 people are due to take part in the study in Ituri and North Kivu. The aim is to measure its effectiveness against the Bundibugyo strain, which is circulating in this outbreak. The WHO notes, however, one essential point: Ervebo is the only licensed Ebola vaccine, but it was developed for the Zaire strain, not Bundibugyo.
This detail matters. In public health, a vaccine that is useful in one epidemic is not necessarily useful in another, even if both are called Ebola. The Congolese decision is therefore a scientific gamble: to obtain robust data in real-world conditions on the potential protection against a less documented variant. It is a pragmatic approach, led in the country by the National Institute of Public Health, with support from the WHO and other partners.
The vaccine rollout is not starting from scratch. The global health agency says teams have already stepped up surveillance, care, sample transport and infection prevention measures. In Kinshasa, the country’s reference laboratory, the National Institute of Biomedical Research confirmed the strain involved from samples taken in the Mongbwalu and Rwampara areas of Ituri.
What the figures tell us beyond the headline toll
The death toll remains the starkest figure. But the response data also tell another story: an epidemic that Congolese teams continue to document day by day, with recovered patients, hospital admissions, isolation and contact monitoring. As of 20 September, an African source of reference also reported that more than 4,500 people had already been vaccinated in the provinces of Tshopo and Bas-Uele, a sign that the response is expanding beyond the most visible corridor.
For residents, the stakes are tangible. In cities such as Bunia and Beni, the risk is linked to travel, markets, health centres and funerals. In rural areas, distance from health facilities makes early detection more difficult. For healthcare workers, the priority is to prevent infection in services already under strain. For the authorities, the challenge is to maintain public trust without playing down the scale of the problem.
The high case fatality rate is a reminder of a reality familiar to epidemiologists: with Ebola, every delay comes at a high cost. The sooner a patient enters the care system, the greater the chances of survival. The WHO also notes that six people have already recovered in the DRC, proof that early care changes clinical outcomes. By contrast, deaths in the community show that the virus is also circulating outside medical facilities.
A Congolese test, a warning for Central Africa
This outbreak extends beyond the DRC’s borders. In a region with intense movement between the DRC, Uganda and neighbouring countries in the Great Lakes region, every new outbreak puts pressure on regional surveillance systems. The WHO has already called on neighbouring states to strengthen screening, community monitoring and diagnostic capacity. The issue is therefore not only Congolese; it also concerns health preparedness across Central Africa and border areas.
At continental level, the situation recalls a simple lesson: the most effective responses combine national institutions, African expertise and international support, without depriving the countries concerned of political and scientific leadership of the response. In the DRC, the Ervebo vaccine trial, the expansion of treatment centres and contact monitoring illustrate this approach. It remains to be seen whether the coming weeks will bring transmission under control in the worst-affected provinces.



